DelveInsight’s ‘Chronic Insomnia—Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Chronic Insomnia, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Chronic Insomnia market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Chronic Insomnia symptoms market size from 2017 to 2030 segmented by seven major markets. The report also covers current Chronic Insomnia symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.
Study Period: 2017–2030
Chronic Insomnia Overview
Insomnia is the most common sleep disorder in the world that carries a huge socio-economic cost. According to the third edition of the International Classification of Sleep Disorders (ICSD-3), insomnia is characterized by difficulty in either initiating sleep, maintaining sleep continuity, or poor sleep quality. For chronic insomnia, sleep disturbances occur at least three times a week and have been present for the last 3 months.
Individuals who have difficulty coping with a stressful situation or report being habitual light sleepers have an elevated propensity to develop chronic insomnia. There is a high rate of association between insomnia and psychiatric disorders like depression, anxiety, and post-traumatic stress disorder. Comorbid medical issues like restless legs syndrome, chronic pain, gastroesophageal reflux disease (GERD), respiratory issues, and immobility are associated with the risk of chronic insomnia.
Chronic insomnia represents a more complex condition than acute transient insomnia. Patients with chronic insomnia usually have accompanying daytime impairment of cognition, mood, or performance that impacts not only the patient and his family, but also affects friends, coworkers, and caretakers. Insomnia patients are more likely to visit hospitals and physicians, have increased absenteeism, make errors or have accidents at work, and have more fatal road accidents. There is also an increased risk for depression, anxiety, substance -use, suicide, and possibly immune dysfunction.
Chronic Insomnia Diagnosis and Treatment
It covers the details of conventional and current medical therapies, and diagnosis available in the Chronic Insomnia market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Chronic Insomnia market report gives a thorough understanding of chronic insomnia symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides chronic insomnia symptoms of treatment algorithms and treatment guidelines for chronic insomnia symptoms in the US, Europe, and Japan.
Diagnosis of insomnia requires a comprehensive assessment of the patient’s medical history, physical examination, and sleeping pattern using various screen tools. These can range from keeping a sleep diary that helps monitor different aspects of sleep behavior to personal monitoring devices like actigraphy which helps record movement during sleep. Once a successful diagnosis is made, the disease must be treated at the earliest since it is associated with numerous comorbidities.
The treatment of chronic insomnia consists of initially diagnosing and treating the underlying medical or psychological problems. Identifying behaviors that may worsen insomnia follows and stopping (or reducing) them would help eliminate insomnia.
Non-pharmacologic interventions for insomnia consist primarily of short-term cognitive-behavioral therapies. These methods act primarily by reducing heightened autonomic and cognitive arousal, modifying self-perpetuating maladaptive sleep habits, altering dysfunctional beliefs and attitudes about sleep, and educating patients about healthier sleep practices.
The Chronic Insomnia symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The total prevalent cases of Chronic Insomnia is increasing in 7MM during the study period, i.e., 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted Chronic Insomnia symptoms epidemiology segmented as the Prevalent cases of Chronic Insomnia, Diagnosed Prevalent cases of Chronic Insomnia, Gender-specific cases of Chronic Insomnia, and Age-specific cases of Chronic Insomnia. The report includes the prevalent scenario of Chronic Insomnia symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
The epidemiology segment also provides the Chronic Insomnia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total number of prevalent cases of Chronic Insomnia associated in 7MM countries was 5,585,128 in 2020.
The chronic insomnia report's drug chapter segment encloses the detailed analysis of Chronic Insomnia early-stage (Phase- I, II, and III) pipeline drugs. It also helps understand the Chronic Insomnia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Chronic Insomnia Emerging Drug
Daridorexant: Idorsia Pharmaceuticals
Daridorexant is a potent, selective, dual orexin receptor antagonist (DORA) currently in development for the treatment of insomnia. Orexin neurons are localized in the lateral hypothalamus and function as a key regulator of wakefulness, signaling other wake-promoting neurons to be active, thus maintaining a "wake state".
Seltorexant: Janssen Research & Development/Minerva Neurosciences
Seltorexant (MIN-202) is an innovative selective orexin 2 receptor antagonist under development to treat insomnia and related mood disorders. Insomnia is the repeated difficulty with sleep initiation, maintenance, or quality that occurs despite adequate time and opportunity for sleep, resulting in daytime impairment. Insomnia can be the primary condition for patients or a secondary symptom of, and contributor to, another medical or psychiatric condition, such as mood disorders or schizophrenia.
Products detail in the report…
The report's Chronic Insomnia market outlook helps build a detailed comprehension of the historic, current, and forecasted Chronic Insomnia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Chronic Insomnia market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Chronic Insomnia market in 7MM is expected to grow in the study period 2017–2030.
Regardless of the type of therapy used, chronic insomnia treatment has two primary objectives: improving sleep quality and quantity, and improving daytime impairments. Initial treatment approaches usually include at least one behavioral intervention, such as stimulus control therapy or relaxation therapy. Biofeedback therapy is also used. Cognitive Behavioral Therapy for Insomnia (CBTI), the most effective and comprehensive non-drug approach to treating insomnia, combines cognitive therapy, behavioral interventions, and sleep hygiene education. The most recent iteration of CBTI is fully automated digital CBTI (dCBTI) and does not require clinician involvement. dCBTI has the scalability to address insomnia as a public health issue. Other non-drug approaches that may have benefits for some patients include relaxation techniques and mindfulness interventions.
Key Findings
This section includes a glimpse of the Chronic Insomnia market in 7MM.
The market size of Chronic Insomnia in the seven major markets was USD 314.2 million in 2020.
The United States Market Outlook
This section provides the total Chronic Insomnia market size and market size by therapies in the United States.
The United States accounts for the largest market size of Chronic Insomnia in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
EU-5 Countries: Market Outlook
The total Chronic Insomnia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Chronic Insomnia market Size and market Size by therapies in Japan are also mentioned.
This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017–2030. The analysis covers the Chronic Insomnia market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Chronic Insomnia key players involved in developing targeted therapeutics.
Major players include Sequential Medicine Ltd., Idorsia Pharmaceuticals, and Janssen Research & Development/Minerva Neurosciences.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Chronic Insomnia emerging therapies.
Approaching reimbursement, proactively, can positively impact both during the early stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
The direct costs of patients with untreated insomnia are significantly higher than those without insomnia. One retrospective study aimed to understand better insomnia's direct healthcare costs is by analyzing claims from a large health plan. Anderson and colleagues found that a diagnosis of insomnia was associated with 26% higher costs at baseline and 46% higher costs at 12 months after diagnosis. When comorbidities were recognized, the insomnia cohort had 80% higher costs, on average, than the matched control cohort. The insomnia cohort experienced greater general health decline as measured by increases in Charlson Comorbidity Index scores, as well as by a greater proportion of patients with mental health diagnoses and use of psychiatric medications, which were drivers in the increase in overall cost.
As insomnia is associated with daytime sleepiness, fatigue, psychomotor deficits, and mood dysregulation, it may be expected to have negative impacts on US workers. Studies have demonstrated the impact of insomnia on impaired workplace functioning, including absenteeism due to sickness, injuries, and disability. Insomnia is a risk factor for workplace accidents and an increased risk of associated falls and injuries, such as hip fractures. The American Insomnia Survey of 4991 respondents revealed that the average costs of insomnia-related accidents and errors are $32,062; these costs were significantly higher than those of other accidents and errors not associated with insomnia ($21,914). Simulations associated insomnia with an estimated 7.2% of all costly workplace accidents and errors, and with 23.7% of the total costs of overall incidents. Annualized US population projected estimates of 274,000 insomnia-related workplace accidents and errors had a combined value of $31.1 billion.
To keep up with current market trends, we take KOLs and SME’s opinion working in the Chronic Insomnia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Chronic Insomnia market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform a Competitive and Market Intelligence analysis of the Chronic Insomnia Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
1. Key Insights
2. Report Introduction
3. Chronic Insomnia Market Overview at a Glance
3.1. Market Share (%) Distribution of Chronic Insomnia in 2018
3.2. Market Share (%) Distribution of Chronic Insomnia in 2030
4. Executive Summary of Chronic Insomnia
5. Disease Background and Overview
5.1. Introduction
5.2. Pathophysiology
5.3. Mechanism of Sleep and Insomnia
5.4. Genetics of Insomnia
5.5. Comorbidities of Chronic Insomnia
5.6. Risk Factors
5.7. Diagnosis
5.8. Differential Diagnosis
5.9. Diagnosis Guidelines
5.10. Treatment
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. 7MM Total Diagnosed Prevalent Population of Chronic Insomnia
6.3. Epidemiology of Chronic Insomnia
6.4. The United States
6.4.1. Prevalence of Insomnia in the United States
6.4.2. Diagnosed Prevalent Cases of Chronic Insomnia in the United States
6.4.3. Gender-specific cases of Chronic Insomnia in the United States
6.4.4. Age-specific Cases of Chronic Insomnia in the United States
6.5. EU5
6.5.1. Germany
6.5.1.1. Prevalence of Insomnia in Germany
6.5.1.2. Diagnosed Prevalent Cases of Chronic Insomnia in Germany
6.5.1.3. Gender-specific cases of Chronic Insomnia in Germany
6.5.1.4. Age-specific Cases of Chronic Insomnia in Germany
6.5.2. France
6.5.2.1. Prevalence of Insomnia in France
6.5.2.2. Diagnosed Prevalent Cases of Chronic Insomnia in France
6.5.2.3. Gender-specific cases of Chronic Insomnia in France
6.5.2.4. Age-specific Cases of Chronic Insomnia in France
6.5.3. Italy
6.5.3.1. Prevalence of Insomnia in Italy
6.5.3.2. Diagnosed Prevalent Cases of Chronic Insomnia in Italy
6.5.3.3. Gender-specific cases of Chronic Insomnia in Italy
6.5.3.4. Age-specific Cases of Chronic Insomnia in Italy
6.5.4. Spain
6.5.4.1. Prevalence of Insomnia in Spain
6.5.4.2. Diagnosed Prevalent Cases of Chronic Insomnia in Spain
6.5.4.3. Gender-specific cases of Chronic Insomnia in Spain
6.5.4.4. Age-specific Cases of Chronic Insomnia in Spain
6.5.5. United Kingdom
6.5.5.1. Prevalence of Insomnia in the United Kingdom
6.5.5.2. Diagnosed Prevalent Cases of Chronic Insomnia in the United Kingdom
6.5.5.3. Gender-specific cases of Chronic Insomnia in the United Kingdom
6.5.5.4. Age-specific Cases of Chronic Insomnia in the United Kingdom
6.6. Japan
6.6.1. Prevalence of Insomnia in Japan
6.6.2. Diagnosed Prevalent Cases of Chronic Insomnia in Japan
6.6.3. Gender-specific cases of Chronic Insomnia in Japan
6.6.4. Age-specific Cases of Chronic Insomnia in Japan
7. Organizations contributing to Chronic Insomnia
8. Patient Journey
9. Case Reports
10. Marketed Products
10.1. Dayvigo (lemborexant): Eisai Inc.
10.1.1. Product Description
10.1.2. Mechanism of action
10.1.3. Regulatory Milestones
10.1.4. Safety and Efficacy of DAYVIGO
10.1.5. Side effects of DAYVIGO
10.1.6. Product Profile
10.2. Belsomra (Suvorexant): Merck & Co.
10.2.1. Product Description
10.2.2. Mechanism of action
10.2.3. Regulatory Milestones
10.2.4. Safety and Efficacy of DAYVIGO
10.2.5. Side effects of DAYVIGO
10.2.6. Product Profile
11. Emerging Therapies
11.1. Key Cross Competition
11.2. Daridorexant: Idorsia Pharmaceuticals
11.2.1. Drug Description
11.2.2. Regulatory Milestones
11.2.3. Clinical Development
11.2.4. Clinical Trials Information
11.2.5. Safety and Efficacy
11.2.6. Product Profile
11.3. Seltorexant: Janssen Research & Development/Minerva Neurosciences
11.3.1. Drug Description
11.3.2. Regulatory Milestones
11.3.3. Clinical Development
11.3.4. Clinical Trials Information
11.3.5. Safety and Efficacy
11.3.6. Product Profile
12. Other Promising Drugs
12.1. SM-1: Sequential Medicine Ltd.
12.1.1. Drug Description
12.1.2. Regulatory Milestones
12.1.3. Clinical Development
12.1.4. Clinical Trials Information
12.1.5. Safety and Efficacy
12.1.6. Product Profile
13. Chronic Insomnia: Seven Major Market Analysis
13.1. Key Findings
13.2. Market Size of Chronic Insomnia in 7MM
13.3. Market Outlook
13.4. United States Market Size
13.4.1. Total Market Size of Chronic Insomnia in the United States
13.4.2. Market Size of Chronic Insomnia by Therapies in the United States
13.5. EU-5 Market Size
13.5.1. Germany
13.5.1.1. Total Market size of Chronic Insomnia in Germany
13.5.1.2. Market Size of Chronic Insomnia by Therapies in Germany
13.5.2. France
13.5.2.1. Total Market size of Chronic Insomnia in France
13.5.2.2. Market Size of Chronic Insomnia by Therapies in France
13.5.3. Italy
13.5.3.1. Total Market size of Chronic Insomnia in Italy
13.5.3.2. Market Size of Chronic Insomnia by Therapies in Italy
13.5.4. Spain
13.5.4.1. Total Market size of Chronic Insomnia in Spain
13.5.4.2. Market Size of Chronic Insomnia by Therapies in Spain
13.5.5. United Kingdom
13.5.5.1. Total Market size of Chronic Insomnia in the United Kingdom
13.5.5.2. Market Size of Chronic Insomnia by Therapies in the United Kingdom
13.6. Japan
13.6.1. Total Market size of Chronic Insomnia in Japan
13.6.2. Market Size of Chronic Insomnia by Therapies in Japan
14. KOL Views
15. Market Drivers
16. Market Barriers
17. SWOT Analysis
18. Unmet Needs
19. Market Access
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
List of Table
Table 1: Summary of Chronic Insomnia, Market, Epidemiology, and Key Events (2018–2030)
Table 2: Diagnosed Prevalent Population of Chronic Insomnia in 7MM in 000’ (2018–2030)
Table 3: Prevalence of Insomnia in the United States in 000’ (2018–2030)
Table 4: Diagnosed Prevalent Cases of Chronic Insomnia in the United States in 000’ (2018–2030)
Table 5: Gender-specific cases of Chronic Insomnia in the United States in 000’ (2018–2030)
Table 6: Age-specific Cases of Chronic Insomnia in the United States in 000’ (2018–2030)
Table 7: Prevalence of Insomnia in Germany in 000’ (2018–2030)
Table 8: Diagnosed Prevalent Cases of Chronic Insomnia in Germany in 000’ (2018–2030)
Table 9: Gender-specific cases of Chronic Insomnia in Germany in 000’ (2018–2030)
Table 10: Age-specific Cases of Chronic Insomnia in Germany (2018–2030)
Table 11: Prevalence of Insomnia in France in 000’ (2018–2030)
Table 12: Diagnosed Prevalent Cases of Chronic Insomnia in France in 000’ (2018–2030)
Table 13: Gender-specific cases of Chronic Insomnia in France in 000’ (2018–2030)
Table 14: Age-specific Cases of Chronic Insomnia in France (2018–2030)
Table 15: Prevalence of Insomnia in Italy in 000’ (2018–2030)
Table 16: Diagnosed Prevalent Cases of Chronic Insomnia in Italy in 000’ (2018–2030)
Table 17: Gender-specific cases of Chronic Insomnia in Italy (2018–2030)
Table 18: Age-specific Cases of Chronic Insomnia in Italy (2018–2030)
Table 19: Prevalence of Insomnia in Spain in 000’ (2018–2030)
Table 20: Diagnosed Prevalent Cases of Chronic Insomnia in Spain in 000’ (2018–2030)
Table 21: Gender-specific cases of Chronic Insomnia in Spain (2018–2030)
Table 22: Age-specific Cases of Chronic Insomnia in Spain in 000’ (2018–2030)
Table 23: Prevalence of Insomnia in the United Kingdom in 000’ (2018–2030)
Table 24: Diagnosed Prevalent Cases of Chronic Insomnia in the United Kingdom in 000’ (2018–2030)
Table 25: Gender-specific cases of Chronic Insomnia in the United Kingdom (2018–2030)
Table 26: Age-specific Cases of Chronic Insomnia in the United Kingdom (2018–2030)
Table 27: Prevalence of Insomnia in Japan in 000’ (2018–2030)
Table 28: Diagnosed Prevalent Cases of Chronic Insomnia in Japan in 000’ (2018–2030)
Table 29: Gender-specific cases of Chronic Insomnia in Japan (2018–2030)
Table 30: Age-specific Cases of Chronic Insomnia in Japan (2018–2030)
Table 31: Organizations contributing towards Chronic Insomnia
Table 33: Daridorexant, Clinical Trial Description, 2020
Table 34: Seltorexant, Clinical Trial Description, 2020
Table 32: SM-1, Clinical Trial Description, 2020
Table 35: 7 Major Market Size of Chronic Insomnia in USD Million (2018–2030)
Table 36: United States Market Size of Chronic Insomnia in USD Million (2018–2030)
Table 37: United States Market Size of Chronic Insomnia by Therapies in USD Million (2018–2030)
Table 38: Germany Market Size of Chronic Insomnia in USD Million (2018–2030)
Table 39: Germany Market Size of Chronic Insomnia by Therapies in USD Million (2018–2030)
Table 40: France Market Size of Chronic Insomnia in USD Million (2018–2030)
Table 41: France Market Size of Chronic Insomnia by Therapies in USD Million (2018–2030)
Table 42: Italy Market Size of Chronic Insomnia in USD Million (2018–2030)
Table 43: Italy Market Size of Chronic Insomnia by Therapies in USD Million (2018–2030)
Table 44: Spain Market Size of Chronic Insomnia in USD Million (2018–2030)
Table 45: Spain Market Size of Chronic Insomnia by Therapies in USD Million (2018–2030)
Table 46: United Kingdom Market Size of Chronic Insomnia in USD Million (2018–2030)
Table 47: United Kingdom Market Size of Chronic Insomnia by Therapies in USD Million (2018–2030)
Table 48: Japan Market Size of Chronic Insomnia in USD Million (2018–2030)
Table 49: Japan Market Size of Chronic Insomnia by Therapies in USD Million (2018–2030)
List of Figures
Figure 1: Comorbidities associated with Chronic Insomnia
Figure 2: Diagnosed Prevalent Population of Chronic Insomnia in 7MM in 000’ (2018–2030)
Figure 3: Prevalence of Insomnia in the United States in 000’ (2018–2030)
Figure 4: Diagnosed Prevalent Cases of Chronic Insomnia in the United States in 000’ (2018–2030)
Figure 5: Gender-specific cases of Chronic Insomnia in the United States in 000’ (2018–2030)
Figure 6: Age-specific Cases of Chronic Insomnia in the United States in 000’ (2018–2030)
Figure 7: Prevalence of Insomnia in Germany in 000’ (2018–2030)
Figure 8: Diagnosed Prevalent Cases of Chronic Insomnia in Germany in 000’ (2018–2030)
Figure 9: Gender-specific cases of Chronic Insomnia in Germany in 000’ (2018–2030)
Figure 10: Age-specific Cases of Chronic Insomnia in Germany in 000’ (2018–2030)
Figure 11: Prevalence of Insomnia in France in 000’ (2018–2030)
Figure 12: Diagnosed Prevalent Cases of Chronic Insomnia in France in 000’ (2018–2030)
Figure 13: Gender-specific cases of Chronic Insomnia in France in 000’ (2018–2030)
Figure 14: Age-specific Cases of Chronic Insomnia in France in 000’ (2018–2030)
Figure 15: Prevalence of Insomnia in Italy in 000’ (2018–2030)
Figure 16: Diagnosed Prevalent Cases of Chronic Insomnia in Italy in 000’ (2018–2030)
Figure 17: Gender-specific cases of Chronic Insomnia in Italy in 000’ (2018–2030)
Figure 18: Age-specific Cases of Chronic Insomnia in Italy in 000’ (2018–2030)
Figure 19: Prevalence of Insomnia in Spain in 000’ (2018–2030)
Figure 20: Diagnosed Prevalent Cases of Chronic Insomnia in Spain in 000’ (2018–2030)
Figure 21: Gender-specific cases of Chronic Insomnia in Spain in 000’ (2018–2030)
Figure 22: Age-specific Cases of Chronic Insomnia in Spain in 000’ (2018–2030)
Figure 23: Prevalence of Insomnia in the United Kingdom in 000’ (2018–2030)
Figure 24: Diagnosed Prevalent Cases of Chronic Insomnia in the United Kingdom in 000’ (2018–2030)
Figure 25: Gender-specific cases of Chronic Insomnia in the United Kingdom in 000’ (2018–2030)
Figure 26: Age-specific Cases of Chronic Insomnia in the United Kingdom in 000’ (2018–2030)
Figure 27: Prevalence of Insomnia in Japan in 000’ (2018–2030)
Figure 28: Diagnosed Prevalent Cases of Chronic Insomnia in Japan in 000’ (2018–2030)
Figure 29: Gender-specific cases of Chronic Insomnia in Japan in 000’ (2018–2030)
Figure 30: Age-specific Cases of Chronic Insomnia in Japan in 000’ (2018–2030)
Figure 31: Seven Major Market Size of Chronic Insomnia in USD Million (2018–2030)
Figure 32: Market Size of Chronic Insomnia in the United States, USD Million (2018–2030)
Figure 33: The United States Market Size of Chronic Insomnia by Therapies in USD Million
Figure 34: Market Size of Chronic Insomnia in Germany, USD Million (2018–2030)
Figure 35: The Germany Market Size of Chronic Insomnia by Therapies in USD Million
Figure 36: Market Size of Chronic Insomnia in France, USD Million (2018–2030)
Figure 37: The France Market Size of Chronic Insomnia by Therapies in USD Million
Figure 38: Market Size of Chronic Insomnia in Italy, USD Million (2018–2030)
Figure 39: The Italy Market Size of Chronic Insomnia by Therapies in USD Million
Figure 40: Market Size of Chronic Insomnia in Spain, USD Million (2018–2030)
Figure 41: The Spain Market Size of Chronic Insomnia by Therapies in USD Million
Figure 42: Market Size of Chronic Insomnia in the United Kingdom, USD Million (2018–2030)
Figure 43: The United Kingdom Market Size of Chronic Insomnia by Therapies in USD Million
Figure 44: Market Size of Chronic Insomnia in Japan, USD Million (2018–2030)
Figure 45: The Japan Market Size of Chronic Insomnia by Therapies in USD Million
Eisai Inc.
Merck & Co.
Idorsia Pharmaceuticals
Janssen Research & Development/Minerva Neurosciences
Sequential Medicine Ltd.
